GlassScriptPhysician profile
Meagan A Holcomb
NPI 1922330901
$4,307.87
in general payments reported to CMS, 2019-2025
38 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.29 · 2022: $176 · 2023: $1,451 · 2024: $843 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,068.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $789.67 | 2023-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $430.40 | 2023-2025 | |
| Lundbeck LLC | $386.27 | 2023-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $257.02 | 2023-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $231.60 | 2023 | Nuplazid |
| Tg Therapeutics, INC. | $208.20 | 2024-2025 | |
| Sk Life Science, INC. | $199.07 | 2021-2025 | Xcopri |
| Neurelis, INC. | $169.48 | 2024-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $130.17 | 2024-2025 | Motpoly Xr |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024 | Zeposia |
| Horizon Therapeutics Plc | $116.66 | 2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $116.19 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $101.92 | 2024-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $92.06 | 2024-2025 | Crexont, Ongentys |
| Pfizer INC. | $91.90 | 2023-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $87.79 | 2024-2025 | Nayzilam, Briviact |
| Amgen INC. | $82.99 | 2022-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $69.31 | 2025 | Dupixent |
| Lilly USA, LLC | $62.57 | 2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $53.04 | 2023-2025 | Nuedexta, Rexulti |
| Corcept Therapeutics | $52.86 | 2025 | Korlym |
| Genentech USA, INC. | $48.96 | 2025 | Ocrevus Zunovo, Ocrevus |
| Celgene Corporation | $47.30 | 2022-2025 | Zeposia |
| Glaxosmithkline, LLC. | $44.59 | 2025 | Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $42.71 | 2025 | |
| Biogen, INC. | $35.83 | 2021-2025 | Vumerity |
| Sanofi-Aventis U.S. LLC | $30.05 | 2025 | |
| Inogen, INC. | $25.67 | 2025 | |
| Sumitomo Pharma America, INC. | $23.01 | 2023 | Aptiom |
| Sunovion Pharmaceuticals INC. | $22.74 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2025 | |
| Electromed, INC. | $18.51 | 2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $17.19 | 2025 | Fasenra |
| Recordati_rare_diseases_inc. | $17.13 | 2025 | Isturisa |
| Cala Health, INC. | $16.32 | 2023 | Cala Trio |
| Axsome Therapeutics, INC. | $14.54 | 2025 | Symbravo |
| Mannkind Corporation | $13.83 | 2025 | |
| Xeris Pharmaceuticals, INC. | $13.62 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Holcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.